Surrozen Inc. is a biopharmaceutical company focused on harnessing the Wnt pathway for applications in regenerative medicine. Founded on breakthrough science from Stanford University and backed by The Column Group, Surrozen is implementing Wnt and R-spondin mimetic approaches with the potential to unlock stem cell control of regeneration in a wide array of human tissues. The Company is building a broad pipeline of selective Wnt pathway targeted antibodies that drive tissue regeneration, with the goal of addressing a variety of critical unmet medical needs.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
03/15/19 | $50,000,000 | Series B |
Hartford HealthCare Endowment Horizons Ventures NS Investment The Column Group | undisclosed |